Thermo Fisher (NYSE: TMO) EVP sells stock under 10b5-1 plan

Rhea-AI Filing Summary

Thermo Fisher Scientific executive vice president Gianluca Pettiti sold 400 shares of common stock in an open-market transaction at $541.20 per share. The sale on February 9, 2026 was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2025.

After this transaction, Pettiti directly beneficially owned 20,752.223 shares of Thermo Fisher Scientific common stock. Rule 10b5-1 plans allow insiders to schedule trades in advance, helping separate personal trading decisions from later corporate developments.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pettiti Gianluca

(Last) (First) (Middle)

168 THIRD AVENUE

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
THERMO FISHER SCIENTIFIC INC. [ TMO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/09/2026		S(1)		400	D	$541.2	20,752.223	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2025.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

	/s/ Melodie T. Morin, Attorney-in-Fact for Gianluca Pettiti	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Thermo Fisher (TMO) report for Gianluca Pettiti?

Thermo Fisher reported that executive vice president Gianluca Pettiti sold 400 shares of common stock at $541.20 per share. The transaction was an open-market sale executed on February 9, 2026 under a pre-arranged Rule 10b5-1 trading plan.

How many Thermo Fisher (TMO) shares did Gianluca Pettiti sell and at what price?

Gianluca Pettiti sold 400 Thermo Fisher common shares at $541.20 each in an open-market transaction. This sale was carried out on February 9, 2026 pursuant to a previously adopted Rule 10b5-1 trading plan.

How many Thermo Fisher (TMO) shares does Gianluca Pettiti own after this sale?

After the reported sale, Gianluca Pettiti beneficially owned 20,752.223 Thermo Fisher common shares directly. This post-transaction balance reflects his holdings immediately following the February 9, 2026 open-market sale reported in the Form 4 filing.

Was the Thermo Fisher (TMO) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted by Gianluca Pettiti on September 12, 2025. Such plans pre-schedule trades, helping separate them from subsequent non-public corporate information.

What is the role of Gianluca Pettiti at Thermo Fisher (TMO) in this Form 4?

In this Form 4, Gianluca Pettiti is identified as an officer of Thermo Fisher Scientific, serving as executive vice president. The filing reports his personal open-market sale of common stock and his resulting directly owned share balance.

Does the Thermo Fisher (TMO) Form 4 involve derivative securities?

No derivative security transactions are listed in the provided Form 4 excerpt. The reported activity involves only Thermo Fisher common stock, specifically a single open-market sale of 400 shares and the updated directly beneficial share ownership afterward.